1140909-48-3 | Cabozantinib s-malate

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$11.00	$8.00
5mg	95%	in stock	$13.00	$9.00
10mg	95%	in stock	$16.00	$11.00
50mg	95%	in stock	$22.00	$16.00
100mg	95%	in stock	$30.00	$21.00
250mg	95%	in stock	$37.00	$26.00
1g	95%	in stock	$44.00	$31.00
5g	95%	in stock	$126.00	$88.00
25g	95%	in stock	$605.00	$423.00

Description

• Catalog Number: AA13452
• Chemical Name: Cabozantinib s-malate
• CAS Number: 1140909-48-3
• Molecular Formula: C32H30FN3O10
• Molecular Weight: 635.5931
• MDL Number: MFCD20923480
• SMILES: OC(=O)C[C@@H](C(=O)O)O.COc1cc2c(ccnc2cc1OC)Oc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F

Computed Properties

• Complexity: 924
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 46
• Hydrogen Bond Acceptor Count: 12
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 11

Literature

• Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

  Expert review of clinical pharmacology 20160101

• Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

  The New England journal of medicine 20151105

• Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  European urology 20120501

• Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

  Cancer discovery 20120301

• c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

  Gastroenterology 20111201

• Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

  Molecular cancer therapeutics 20111201

• Novel therapies for metastatic castrate-resistant prostate cancer.

  Journal of the National Cancer Institute 20111116

• Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

  Drugs of today (Barcelona, Spain : 1998) 20111101

• VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

  Cancer research 20110715

• Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

  The Journal of clinical endocrinology and metabolism 20110601

• XL184 (cabozantinib) for medullary thyroid carcinoma.

  Expert opinion on investigational drugs 20110301

• Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.

  Endocrine journal 20110101

• Novel treatment of medullary thyroid cancer.

  Current opinion in endocrinology, diabetes, and obesity 20091001